Related references
Note: Only part of the references are listed.P407 Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
L Peyrin-Biroulet et al.
Journal of Crohns & Colitis (2023)
Systematic review of therapies for refractory ulcerative proctitis
Sreecanth S. Raja et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2023)
IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus
Benedicte Caron et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
Efficacy of Pharmacological Agents for Ulcerative Proctitis: A Systematic Literature Review
Benedicte Caron et al.
JOURNAL OF CROHNS & COLITIS (2022)
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Katsuyoshi Matsuoka et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)
Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial
Wolfgang Kruis et al.
JOURNAL OF CROHNS & COLITIS (2022)
Drug development for ulcerative proctitis: current concepts
Benedicte Caron et al.
GUT (2021)
Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis
Guillaume Pineton de Chambrun et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
No Superiority of Tacrolimus Suppositories vs Beclomethasone Suppositories in a Randomized Trial of Patients With Refractory Ulcerative Proctitis
Mitchell R. K. L. Lie et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Long-term outcomes of patients with ulcerative proctitis: Analysis from a large referral centre cohort
Dubois Evelyne et al.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2020)
Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis
Wolfgang Kruis et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study
Makoto Naganuma et al.
JOURNAL OF GASTROENTEROLOGY (2018)
Acute severe ulcerative colitis: latest evidence and therapeutic implications
Parambir S. Dulai et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2018)
Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study
A. Hochart et al.
GUT (2017)
A 20-Year Temporal Change Analysis in Incidence, Presenting Phenotype and Mortality, in the Dutch IBDSL Cohort-Can Diagnostic Factors Explain the Increase in IBD Incidence?
Tim R. A. van den Heuvel et al.
JOURNAL OF CROHNS & COLITIS (2017)
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management
Marcus Harbord et al.
JOURNAL OF CROHNS & COLITIS (2017)
Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis
Ian C. Lawrance et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Coliti
Makoto Naganuma et al.
JOURNAL OF CROHNS & COLITIS (2016)
Comparison of Rectal With Oral Mesalazine in the Treatment of Rectal Ulcerative Proctitis (CORRECT Study)
Shingo Kato et al.
GASTROENTEROLOGY (2016)
Budesonide Foam Induces Remission in Patients With Mild to Moderate Ulcerative Proctitis and Ulcerative Proctosigmoiditis
William J. Sandborn et al.
GASTROENTEROLOGY (2015)
Drug Therapies for Ulcerative Proctitis: Systematic Review and Meta-analysis
Mitchell R. K. L. Lie et al.
INFLAMMATORY BOWEL DISEASES (2014)
Proximal disease extension and related predicting factors in ulcerative proctitis
Bun Kim et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2014)
Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation - a placebo-controlled study
M. Watanabe et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
A Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Mesalamine Suppositories 1 g at Bedtime and 500 mg Twice Daily in Patients with Active Mild-to-Moderate Ulcerative Proctitis
Mark Lamet
DIGESTIVE DISEASES AND SCIENCES (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Infliximab for refractory ulcerative proctitis
G. Bouguen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Direct Comparison of Two Different Mesalamine Formulations for the Induction of Remission in Patients with Ulcerative Colitis: A Double-blind, Randomized Study
Hiroaki Ito et al.
INFLAMMATORY BOWEL DISEASES (2010)
Clinical Trial: A Novel High-dose 1 g Mesalamine Suppository (Salofalk) Once Daily Is as Efficacious as a 500-mg Suppository Thrice Daily in Active Ulcerative Proctitis
Tilo Andus et al.
INFLAMMATORY BOWEL DISEASES (2010)
Conducting Meta-Analyses in R with the metafor Package
Wolfgang Viechtbauer
JOURNAL OF STATISTICAL SOFTWARE (2010)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis
R. Eliakim et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis
V Gross et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2006)
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II trial
SB Hanauer et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
RDP58 is a novel and potentially effective oral therapy for ulcerative colitis
S Travis et al.
INFLAMMATORY BOWEL DISEASES (2005)
Efficacy and safety of mesalamine 1 g HS versus 500 mg BID suppositories in mild to moderate ulcerative proctitis: A multicenter randomized study
M Lamet et al.
INFLAMMATORY BOWEL DISEASES (2005)
Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine - A single-blind randomized controlled trial
P Gionchetti et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2005)
Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis
A Sinha et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Budesonide foam as a new therapeutic concept in the therapy of distal ulcerative colitis in comparison to mesalazine enemas.: An open, controlled, randomized and prospective multicenter pilot study
W Rufle et al.
ZEITSCHRIFT FUR GASTROENTEROLOGIE (2000)
Share Paper
